Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biscotti T, Biagetti S, Bearzi I, Cascinu S. Scartozzi M, et al. Among authors: zaniboni a. Oncologist. 2011;16(1):53-60. doi: 10.1634/theoncologist.2010-0119. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212430 Free PMC article.
[Metastatic colorectal cancer: adjournments from ESMO 2006].
Bonetti A, Cascinu S, Falcone A, Maiello E, Zaniboni A, Aschele C. Bonetti A, et al. Among authors: zaniboni a. Tumori. 2006 Nov-Dec;92(6):1-12. doi: 10.1177/030089160609200627. Tumori. 2006. PMID: 17262903 Italian. No abstract available.
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: zaniboni a. J Clin Oncol. 2007 Sep 1;25(25):3930-5. doi: 10.1200/JCO.2007.11.5022. J Clin Oncol. 2007. PMID: 17761976
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu S, et al. Among authors: zaniboni a. Lancet Oncol. 2008 Jan;9(1):39-44. doi: 10.1016/S1470-2045(07)70383-2. Lancet Oncol. 2008. PMID: 18077217 Clinical Trial.
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.
Mandalà M, Barni S, Floriani I, Isa L, Fornarini G, Marangolo M, Mosconi S, Corsi D, Rulli E, Frontini L, Cortesi E, Zaniboni A, Aglietta M, Labianca R. Mandalà M, et al. Among authors: zaniboni a. Eur J Cancer. 2009 Jan;45(1):65-73. doi: 10.1016/j.ejca.2008.09.005. Epub 2008 Dec 8. Eur J Cancer. 2009. PMID: 19068274 Clinical Trial.
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: zaniboni a. BMC Cancer. 2009 Aug 27;9:303. doi: 10.1186/1471-2407-9-303. BMC Cancer. 2009. PMID: 19712476 Free PMC article.
363 results